Low PE Pharma Giant Jumps Over 4% After Q4FY26 Results; PAT Declines 55%, Announces Rs 13 Per Share Dividend

Indian equity benchmark indices traded higher on Wednesday, with the benchmark Nifty 50 index rising 0.54 per cent to 23,504.70 during the session. Positive sentiment in frontline indices supported sector-specific buying. In this segment, Cipla's share price remained in focus after the company announced its Q4FY26 and FY26 consolidated financial results. On Wednesday, Cipla share price Jumps 4.31 per cent to Rs 1,348.00, while the Nifty Pharma index also traded higher during the session.

Cipla Q4FY26 Results

Cipla reported consolidated revenue from operations of Rs 6,541 crore in Q4FY26 as against Rs 6,730 crore reported in Q4FY25.

EBITDA for the quarter stood at Rs 997 crore compared to Rs 1,538 crore reported in the corresponding quarter previous year. EBITDA margin came in at 15.2 per cent during Q4FY26 as against 22.8 per cent reported in Q4FY25.

Profit after Tax attributable to shareholders stood at Rs 555 crore in Q4FY26 as against Rs 1,222 crore reported in Q4FY25, reflecting a decline of around 55 per cent YoY.

The company stated that it delivered double-digit growth across three segments during the quarter despite multiple headwinds.

Cipla FY26 Performance

For the financial year ended March 31, 2026, Cipla reported consolidated revenue from operations of Rs 28,163 crore as against Rs 27,548 crore reported in FY25, registering a growth of around 2 per cent YoY.

EBITDA for FY26 stood at Rs 5,925 crore compared to Rs 7,128 crore reported in FY25, while EBITDA margin came in at 21.0 per cent.

Profit after tax attributable to shareholders stood at Rs 3,879 crore during FY26 as against Rs 5,273 crore reported in FY25, witnessing a decline of around 26 per cent YoY.

Cipla Revenue Breakdown

Cipla’s One India business reported FY26 revenue of Rs 12,680 crore, while Q4FY26 revenue stood at Rs 3,007 crore, supported by double-digit growth across branded prescription, trade generics and consumer health businesses.

North America business revenue stood at USD 780 million during FY26, while One Africa business revenue came in at USD 483 million. Emerging Markets and Europe business crossed the USD 400 million revenue benchmark during FY26.

Dividend Announcement

The Board of Directors recommended a final dividend of Rs 13 per equity share for the financial year ended March 31, 2026, subject to approval of shareholders at the ensuing Annual General Meeting.

Key Business Developments

During FY26, Cipla received regulatory approval for the first AB-rated gVentolin with CGT, representing the first commercial MDI product to be manufactured from its U.S. facility.

The company also partnered with MannKind to launch India’s only rapid-acting inhaled insulin and secured rights from Eli Lilly to distribute and promote Yurpeak in India.

Cipla further launched Ciplostem, a DCGI-approved allogeneic MSC therapy for Knee Osteoarthritis, and strengthened its Neuro/CNS portfolio through acquisition of three brands addressing neuropathic pain and sleep disorders.

During FY26, the company maintained a strong balance sheet with total cash and cash equivalents of Rs 11,140 crore and continued investments towards growth initiatives and pipeline expansion.

About Cipla

Cipla Ltd is a global pharmaceutical company engaged in the development, manufacturing and marketing of respiratory, anti-retroviral, urology, cardiac, anti-diabetic and consumer healthcare products. The company operates across India, North America, Africa, Europe and other international markets.

Share your views on Cipla’s Q4FY26 performance and global expansion strategy in the comments below.
Disclaimer: This article is for informational purposes only and not investment advice.